Optimization Manufacture of Virus- and Tumor-Specific T Cells-Reference-Cited by-同舟云学术

Optimization Manufacture of Virus- and Tumor-Specific T Cells

Published:2011 Issue: Volume:2011 Page:1-8
ISSN:1687-966X
Container-title:Stem Cells International
language:en
Short-container-title:Stem Cells International

Author:

Lapteva Natalia¹,Vera Juan F.¹

Affiliation:

1. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX77030, USA

Abstract

Althoughex vivoexpanded T cells are currently widely used in pre-clinical and clinical trials, the complexity of manufacture remains a major impediment for broader application. In this review we discuss current protocols for theex vivoexpansion of virus- and tumor-specific T cells and describe our experience in manufacture optimization using a gas-permeable static culture flask (G-Rex). This innovative device has revolutionized the manufacture process by allowing us to increase cell yields while decreasing the frequency of cell manipulation andin vitroculture time. It is now being used in good manufacturing practice (GMP) facilities for clinical cell production in our institution as well as many others in the US and worldwide.

Publisher

Hindawi Limited

Subject

Cell Biology,Molecular Biology

Link

http://downloads.hindawi.com/journals/sci/2011/434392.pdf

Reference35 articles.

1. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

2. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers

3. Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

4. Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

5. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial;Annals of Oncology;2024-09

2. How can Cytokine-induced killer cells overcome CAR-T cell limits;Frontiers in Immunology;2023-08-22

3. Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies;Bioengineering;2022-12-15

4. In-situ scalable manufacturing of Epstein–Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA);Scientific Reports;2022-04-29

5. Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use;Cytotherapy;2022-03